nodes	percent_of_prediction	percent_of_DWPC	metapath
Naphazoline—NISCH—Podofilox—Teniposide—hematologic cancer	0.00539	0.226	CbGdCrCtD
Naphazoline—NISCH—Menadione—Thalidomide—hematologic cancer	0.00409	0.171	CbGdCrCtD
Naphazoline—NISCH—Vincristine—Vinorelbine—hematologic cancer	0.00343	0.144	CbGdCrCtD
Naphazoline—NISCH—Podofilox—Etoposide—hematologic cancer	0.00321	0.135	CbGdCrCtD
Naphazoline—NISCH—blood—hematologic cancer	0.00294	0.109	CbGeAlD
Naphazoline—NISCH—bone marrow—hematologic cancer	0.00285	0.106	CbGeAlD
Naphazoline—NISCH—Vinblastine—Vinorelbine—hematologic cancer	0.00276	0.116	CbGdCrCtD
Naphazoline—NISCH—Vincristine—Vinblastine—hematologic cancer	0.00275	0.115	CbGdCrCtD
Naphazoline—NISCH—lung—hematologic cancer	0.00258	0.0957	CbGeAlD
Naphazoline—NISCH—testis—hematologic cancer	0.00243	0.0903	CbGeAlD
Naphazoline—NISCH—Vinblastine—Vincristine—hematologic cancer	0.00221	0.0926	CbGdCrCtD
Naphazoline—ADRA1A—hematopoietic system—hematologic cancer	0.00213	0.079	CbGeAlD
Naphazoline—NISCH—lymph node—hematologic cancer	0.00176	0.0655	CbGeAlD
Naphazoline—ADRA2A—hematopoietic system—hematologic cancer	0.00162	0.0601	CbGeAlD
Naphazoline—ADRA1A—blood—hematologic cancer	0.00141	0.0523	CbGeAlD
Naphazoline—ADRA2C—blood—hematologic cancer	0.00134	0.0499	CbGeAlD
Naphazoline—ADRA2A—gonad—hematologic cancer	0.00123	0.0457	CbGeAlD
Naphazoline—ADRA2C—lung—hematologic cancer	0.00118	0.0437	CbGeAlD
Naphazoline—Discomfort—Bleomycin—hematologic cancer	0.00117	0.00168	CcSEcCtD
Naphazoline—Nausea—Methoxsalen—hematologic cancer	0.00117	0.00168	CcSEcCtD
Naphazoline—Nervousness—Alitretinoin—hematologic cancer	0.00117	0.00168	CcSEcCtD
Naphazoline—Discomfort—Vinorelbine—hematologic cancer	0.00115	0.00165	CcSEcCtD
Naphazoline—Vision blurred—Carmustine—hematologic cancer	0.00114	0.00164	CcSEcCtD
Naphazoline—Asthenia—Procarbazine—hematologic cancer	0.00114	0.00163	CcSEcCtD
Naphazoline—Nausea—Mercaptopurine—hematologic cancer	0.00114	0.00163	CcSEcCtD
Naphazoline—Headache—Idarubicin—hematologic cancer	0.00113	0.00163	CcSEcCtD
Naphazoline—Vision blurred—Alitretinoin—hematologic cancer	0.00113	0.00163	CcSEcCtD
Naphazoline—Erythema—Mitoxantrone—hematologic cancer	0.00113	0.00162	CcSEcCtD
Naphazoline—Hypertension—Thiotepa—hematologic cancer	0.00113	0.00162	CcSEcCtD
Naphazoline—Nausea—Clofarabine—hematologic cancer	0.00112	0.00161	CcSEcCtD
Naphazoline—Nausea—Daunorubicin—hematologic cancer	0.00112	0.00161	CcSEcCtD
Naphazoline—Vision blurred—Ifosfamide—hematologic cancer	0.00112	0.00161	CcSEcCtD
Naphazoline—Nausea—Anagrelide—hematologic cancer	0.00111	0.0016	CcSEcCtD
Naphazoline—Nausea—Pentostatin—hematologic cancer	0.00111	0.0016	CcSEcCtD
Naphazoline—Asthenia—Bexarotene—hematologic cancer	0.00111	0.0016	CcSEcCtD
Naphazoline—Asthenia—Dasatinib—hematologic cancer	0.00111	0.0016	CcSEcCtD
Naphazoline—ADRA2C—testis—hematologic cancer	0.00111	0.0413	CbGeAlD
Naphazoline—Asthenia—Fludarabine—hematologic cancer	0.00111	0.0016	CcSEcCtD
Naphazoline—Hyperhidrosis—Bortezomib—hematologic cancer	0.00111	0.00159	CcSEcCtD
Naphazoline—Somnolence—Lenalidomide—hematologic cancer	0.0011	0.00159	CcSEcCtD
Naphazoline—Headache—Teniposide—hematologic cancer	0.0011	0.00159	CcSEcCtD
Naphazoline—Eye disorder—Cisplatin—hematologic cancer	0.0011	0.00158	CcSEcCtD
Naphazoline—Erythema—Gemcitabine—hematologic cancer	0.0011	0.00158	CcSEcCtD
Naphazoline—Hypertension—Thalidomide—hematologic cancer	0.00109	0.00157	CcSEcCtD
Naphazoline—Somnolence—Hydroxyurea—hematologic cancer	0.00109	0.00157	CcSEcCtD
Naphazoline—Dizziness—Busulfan—hematologic cancer	0.00108	0.00155	CcSEcCtD
Naphazoline—Nausea—Idarubicin—hematologic cancer	0.00108	0.00155	CcSEcCtD
Naphazoline—ADRA2A—blood—hematologic cancer	0.00107	0.0398	CbGeAlD
Naphazoline—Vision blurred—Mitoxantrone—hematologic cancer	0.00106	0.00153	CcSEcCtD
Naphazoline—Discomfort—Thalidomide—hematologic cancer	0.00106	0.00153	CcSEcCtD
Naphazoline—Asthenia—Chlorambucil—hematologic cancer	0.00105	0.00151	CcSEcCtD
Naphazoline—Hypertension—Carmustine—hematologic cancer	0.00105	0.00151	CcSEcCtD
Naphazoline—Dizziness—Procarbazine—hematologic cancer	0.00105	0.00151	CcSEcCtD
Naphazoline—Nausea—Teniposide—hematologic cancer	0.00105	0.0015	CcSEcCtD
Naphazoline—Hypertension—Alitretinoin—hematologic cancer	0.00104	0.00149	CcSEcCtD
Naphazoline—Asthenia—Nilotinib—hematologic cancer	0.00103	0.00148	CcSEcCtD
Naphazoline—Dizziness—Dasatinib—hematologic cancer	0.00103	0.00148	CcSEcCtD
Naphazoline—Dizziness—Bexarotene—hematologic cancer	0.00103	0.00148	CcSEcCtD
Naphazoline—Hypertension—Ifosfamide—hematologic cancer	0.00103	0.00148	CcSEcCtD
Naphazoline—Erythema—Cisplatin—hematologic cancer	0.00102	0.00147	CcSEcCtD
Naphazoline—Asthenia—Imatinib—hematologic cancer	0.00102	0.00147	CcSEcCtD
Naphazoline—Headache—Busulfan—hematologic cancer	0.00102	0.00147	CcSEcCtD
Naphazoline—Discomfort—Alitretinoin—hematologic cancer	0.00101	0.00145	CcSEcCtD
Naphazoline—Eye disorder—Etoposide—hematologic cancer	0.00101	0.00145	CcSEcCtD
Naphazoline—Asthenia—Cladribine—hematologic cancer	0.001	0.00145	CcSEcCtD
Naphazoline—Hypertension—Vincristine—hematologic cancer	0.001	0.00144	CcSEcCtD
Naphazoline—Hyperglycaemia—Betamethasone—hematologic cancer	0.001	0.00144	CcSEcCtD
Naphazoline—Hyperglycaemia—Dexamethasone—hematologic cancer	0.001	0.00144	CcSEcCtD
Naphazoline—Discomfort—Ifosfamide—hematologic cancer	0.000999	0.00144	CcSEcCtD
Naphazoline—Hyperhidrosis—Thalidomide—hematologic cancer	0.000997	0.00143	CcSEcCtD
Naphazoline—Headache—Procarbazine—hematologic cancer	0.000992	0.00143	CcSEcCtD
Naphazoline—Hypertension—Mitoxantrone—hematologic cancer	0.000974	0.0014	CcSEcCtD
Naphazoline—Hypertension—Irinotecan—hematologic cancer	0.000974	0.0014	CcSEcCtD
Naphazoline—Headache—Dasatinib—hematologic cancer	0.000972	0.0014	CcSEcCtD
Naphazoline—Headache—Bexarotene—hematologic cancer	0.000972	0.0014	CcSEcCtD
Naphazoline—Headache—Fludarabine—hematologic cancer	0.000969	0.00139	CcSEcCtD
Naphazoline—Nausea—Busulfan—hematologic cancer	0.000969	0.00139	CcSEcCtD
Naphazoline—Eye pain—Epirubicin—hematologic cancer	0.000967	0.00139	CcSEcCtD
Naphazoline—Vision blurred—Cisplatin—hematologic cancer	0.000965	0.00139	CcSEcCtD
Naphazoline—Asthenia—Vinblastine—hematologic cancer	0.000964	0.00139	CcSEcCtD
Naphazoline—Discomfort—Mitoxantrone—hematologic cancer	0.000949	0.00136	CcSEcCtD
Naphazoline—Discomfort—Irinotecan—hematologic cancer	0.000949	0.00136	CcSEcCtD
Naphazoline—Hypertension—Gemcitabine—hematologic cancer	0.000949	0.00136	CcSEcCtD
Naphazoline—Hyperhidrosis—Alitretinoin—hematologic cancer	0.000948	0.00136	CcSEcCtD
Naphazoline—Dizziness—Nilotinib—hematologic cancer	0.000948	0.00136	CcSEcCtD
Naphazoline—Somnolence—Thiotepa—hematologic cancer	0.000948	0.00136	CcSEcCtD
Naphazoline—Dizziness—Imatinib—hematologic cancer	0.000943	0.00136	CcSEcCtD
Naphazoline—Nausea—Procarbazine—hematologic cancer	0.00094	0.00135	CcSEcCtD
Naphazoline—ADRA2A—lung—hematologic cancer	0.00094	0.0349	CbGeAlD
Naphazoline—Hyperhidrosis—Ifosfamide—hematologic cancer	0.000937	0.00135	CcSEcCtD
Naphazoline—Dizziness—Cladribine—hematologic cancer	0.000926	0.00133	CcSEcCtD
Naphazoline—Erythema—Prednisolone—hematologic cancer	0.000925	0.00133	CcSEcCtD
Naphazoline—Discomfort—Gemcitabine—hematologic cancer	0.000924	0.00133	CcSEcCtD
Naphazoline—Nausea—Bexarotene—hematologic cancer	0.000922	0.00133	CcSEcCtD
Naphazoline—Nausea—Dasatinib—hematologic cancer	0.000922	0.00133	CcSEcCtD
Naphazoline—Nausea—Fludarabine—hematologic cancer	0.000919	0.00132	CcSEcCtD
Naphazoline—Asthenia—Melphalan—hematologic cancer	0.000917	0.00132	CcSEcCtD
Naphazoline—Somnolence—Thalidomide—hematologic cancer	0.000917	0.00132	CcSEcCtD
Naphazoline—Hyperhidrosis—Vincristine—hematologic cancer	0.000914	0.00131	CcSEcCtD
Naphazoline—Headache—Nilotinib—hematologic cancer	0.000898	0.00129	CcSEcCtD
Naphazoline—Eye pain—Doxorubicin—hematologic cancer	0.000895	0.00129	CcSEcCtD
Naphazoline—Headache—Imatinib—hematologic cancer	0.000893	0.00128	CcSEcCtD
Naphazoline—Asthenia—Lenalidomide—hematologic cancer	0.000891	0.00128	CcSEcCtD
Naphazoline—Hyperhidrosis—Mitoxantrone—hematologic cancer	0.00089	0.00128	CcSEcCtD
Naphazoline—Hyperhidrosis—Irinotecan—hematologic cancer	0.00089	0.00128	CcSEcCtD
Naphazoline—Dizziness—Vinblastine—hematologic cancer	0.000888	0.00128	CcSEcCtD
Naphazoline—ADRA2A—testis—hematologic cancer	0.000887	0.0329	CbGeAlD
Naphazoline—Somnolence—Carmustine—hematologic cancer	0.00088	0.00127	CcSEcCtD
Naphazoline—Asthenia—Hydroxyurea—hematologic cancer	0.000879	0.00126	CcSEcCtD
Naphazoline—Headache—Cladribine—hematologic cancer	0.000877	0.00126	CcSEcCtD
Naphazoline—Vision blurred—Prednisolone—hematologic cancer	0.000872	0.00125	CcSEcCtD
Naphazoline—Somnolence—Alitretinoin—hematologic cancer	0.000872	0.00125	CcSEcCtD
Naphazoline—Nausea—Chlorambucil—hematologic cancer	0.000871	0.00125	CcSEcCtD
Naphazoline—Hyperglycaemia—Prednisone—hematologic cancer	0.000871	0.00125	CcSEcCtD
Naphazoline—Hyperhidrosis—Gemcitabine—hematologic cancer	0.000867	0.00125	CcSEcCtD
Naphazoline—Somnolence—Ifosfamide—hematologic cancer	0.000862	0.00124	CcSEcCtD
Naphazoline—Discomfort—Cisplatin—hematologic cancer	0.000862	0.00124	CcSEcCtD
Naphazoline—Nausea—Nilotinib—hematologic cancer	0.000852	0.00122	CcSEcCtD
Naphazoline—Erythema—Triamcinolone—hematologic cancer	0.000851	0.00122	CcSEcCtD
Naphazoline—Nausea—Imatinib—hematologic cancer	0.000847	0.00122	CcSEcCtD
Naphazoline—Headache—Vinblastine—hematologic cancer	0.000841	0.00121	CcSEcCtD
Naphazoline—Nausea—Cladribine—hematologic cancer	0.000832	0.0012	CcSEcCtD
Naphazoline—Eye disorder—Dexamethasone—hematologic cancer	0.000829	0.00119	CcSEcCtD
Naphazoline—Eye disorder—Betamethasone—hematologic cancer	0.000829	0.00119	CcSEcCtD
Naphazoline—Dizziness—Lenalidomide—hematologic cancer	0.000822	0.00118	CcSEcCtD
Naphazoline—Asthenia—Bortezomib—hematologic cancer	0.00082	0.00118	CcSEcCtD
Naphazoline—Somnolence—Mitoxantrone—hematologic cancer	0.000818	0.00118	CcSEcCtD
Naphazoline—Somnolence—Irinotecan—hematologic cancer	0.000818	0.00118	CcSEcCtD
Naphazoline—Asthenia—Bleomycin—hematologic cancer	0.000814	0.00117	CcSEcCtD
Naphazoline—Hypertension—Etoposide—hematologic cancer	0.00081	0.00116	CcSEcCtD
Naphazoline—Dizziness—Hydroxyurea—hematologic cancer	0.00081	0.00116	CcSEcCtD
Naphazoline—Hyperhidrosis—Cisplatin—hematologic cancer	0.000808	0.00116	CcSEcCtD
Naphazoline—ADRA2C—lymph node—hematologic cancer	0.000806	0.0299	CbGeAlD
Naphazoline—Asthenia—Vinorelbine—hematologic cancer	0.000801	0.00115	CcSEcCtD
Naphazoline—Hypertension—Prednisolone—hematologic cancer	0.000799	0.00115	CcSEcCtD
Naphazoline—Nausea—Vinblastine—hematologic cancer	0.000798	0.00115	CcSEcCtD
Naphazoline—Somnolence—Gemcitabine—hematologic cancer	0.000797	0.00115	CcSEcCtD
Naphazoline—Discomfort—Etoposide—hematologic cancer	0.000789	0.00114	CcSEcCtD
Naphazoline—Discomfort—Prednisolone—hematologic cancer	0.000778	0.00112	CcSEcCtD
Naphazoline—Headache—Lenalidomide—hematologic cancer	0.000778	0.00112	CcSEcCtD
Naphazoline—Erythema—Betamethasone—hematologic cancer	0.000772	0.00111	CcSEcCtD
Naphazoline—Erythema—Dexamethasone—hematologic cancer	0.000772	0.00111	CcSEcCtD
Naphazoline—Headache—Hydroxyurea—hematologic cancer	0.000767	0.0011	CcSEcCtD
Naphazoline—Asthenia—Thiotepa—hematologic cancer	0.000765	0.0011	CcSEcCtD
Naphazoline—Nausea—Melphalan—hematologic cancer	0.000759	0.00109	CcSEcCtD
Naphazoline—Dizziness—Bortezomib—hematologic cancer	0.000756	0.00109	CcSEcCtD
Naphazoline—Hyperhidrosis—Etoposide—hematologic cancer	0.00074	0.00106	CcSEcCtD
Naphazoline—Asthenia—Thalidomide—hematologic cancer	0.00074	0.00106	CcSEcCtD
Naphazoline—Dizziness—Vinorelbine—hematologic cancer	0.000738	0.00106	CcSEcCtD
Naphazoline—Nausea—Lenalidomide—hematologic cancer	0.000738	0.00106	CcSEcCtD
Naphazoline—Hypertension—Triamcinolone—hematologic cancer	0.000735	0.00106	CcSEcCtD
Naphazoline—Hyperhidrosis—Prednisolone—hematologic cancer	0.00073	0.00105	CcSEcCtD
Naphazoline—Nausea—Hydroxyurea—hematologic cancer	0.000728	0.00105	CcSEcCtD
Naphazoline—Eye disorder—Prednisone—hematologic cancer	0.000722	0.00104	CcSEcCtD
Naphazoline—Drowsiness—Methotrexate—hematologic cancer	0.000719	0.00103	CcSEcCtD
Naphazoline—Headache—Bortezomib—hematologic cancer	0.000716	0.00103	CcSEcCtD
Naphazoline—Discomfort—Triamcinolone—hematologic cancer	0.000716	0.00103	CcSEcCtD
Naphazoline—Asthenia—Carmustine—hematologic cancer	0.000711	0.00102	CcSEcCtD
Naphazoline—Dizziness—Thiotepa—hematologic cancer	0.000705	0.00101	CcSEcCtD
Naphazoline—Asthenia—Alitretinoin—hematologic cancer	0.000704	0.00101	CcSEcCtD
Naphazoline—Headache—Vinorelbine—hematologic cancer	0.000699	0.00101	CcSEcCtD
Naphazoline—Asthenia—Ifosfamide—hematologic cancer	0.000696	0.001	CcSEcCtD
Naphazoline—Sweating—Methotrexate—hematologic cancer	0.000689	0.000992	CcSEcCtD
Naphazoline—Dizziness—Thalidomide—hematologic cancer	0.000682	0.000981	CcSEcCtD
Naphazoline—Hyperglycaemia—Epirubicin—hematologic cancer	0.000681	0.000979	CcSEcCtD
Naphazoline—Somnolence—Etoposide—hematologic cancer	0.000681	0.000979	CcSEcCtD
Naphazoline—Nausea—Bortezomib—hematologic cancer	0.000679	0.000977	CcSEcCtD
Naphazoline—Asthenia—Vincristine—hematologic cancer	0.000678	0.000975	CcSEcCtD
Naphazoline—Nausea—Bleomycin—hematologic cancer	0.000674	0.000969	CcSEcCtD
Naphazoline—Drowsiness—Epirubicin—hematologic cancer	0.000673	0.000968	CcSEcCtD
Naphazoline—Erythema—Prednisone—hematologic cancer	0.000672	0.000967	CcSEcCtD
Naphazoline—Hyperhidrosis—Triamcinolone—hematologic cancer	0.000671	0.000966	CcSEcCtD
Naphazoline—Headache—Thiotepa—hematologic cancer	0.000668	0.00096	CcSEcCtD
Naphazoline—Hypertension—Dexamethasone—hematologic cancer	0.000667	0.000959	CcSEcCtD
Naphazoline—Hypertension—Betamethasone—hematologic cancer	0.000667	0.000959	CcSEcCtD
Naphazoline—Nausea—Vinorelbine—hematologic cancer	0.000663	0.000954	CcSEcCtD
Naphazoline—Asthenia—Irinotecan—hematologic cancer	0.000661	0.00095	CcSEcCtD
Naphazoline—Asthenia—Mitoxantrone—hematologic cancer	0.000661	0.00095	CcSEcCtD
Naphazoline—Dizziness—Carmustine—hematologic cancer	0.000655	0.000942	CcSEcCtD
Naphazoline—Discomfort—Dexamethasone—hematologic cancer	0.00065	0.000934	CcSEcCtD
Naphazoline—Discomfort—Betamethasone—hematologic cancer	0.00065	0.000934	CcSEcCtD
Naphazoline—Dizziness—Alitretinoin—hematologic cancer	0.000649	0.000933	CcSEcCtD
Naphazoline—Headache—Thalidomide—hematologic cancer	0.000646	0.000929	CcSEcCtD
Naphazoline—Sweating—Epirubicin—hematologic cancer	0.000645	0.000928	CcSEcCtD
Naphazoline—Asthenia—Gemcitabine—hematologic cancer	0.000643	0.000925	CcSEcCtD
Naphazoline—ADRA2A—lymph node—hematologic cancer	0.000643	0.0239	CbGeAlD
Naphazoline—Dizziness—Ifosfamide—hematologic cancer	0.000641	0.000922	CcSEcCtD
Naphazoline—Vision blurred—Prednisone—hematologic cancer	0.000634	0.000911	CcSEcCtD
Naphazoline—Nausea—Thiotepa—hematologic cancer	0.000633	0.000911	CcSEcCtD
Naphazoline—Hyperglycaemia—Doxorubicin—hematologic cancer	0.00063	0.000906	CcSEcCtD
Naphazoline—Dizziness—Vincristine—hematologic cancer	0.000625	0.000899	CcSEcCtD
Naphazoline—Drowsiness—Doxorubicin—hematologic cancer	0.000623	0.000896	CcSEcCtD
Naphazoline—Headache—Carmustine—hematologic cancer	0.00062	0.000892	CcSEcCtD
Naphazoline—Headache—Alitretinoin—hematologic cancer	0.000615	0.000884	CcSEcCtD
Naphazoline—Nausea—Thalidomide—hematologic cancer	0.000612	0.000881	CcSEcCtD
Naphazoline—Hyperhidrosis—Dexamethasone—hematologic cancer	0.000609	0.000876	CcSEcCtD
Naphazoline—Hyperhidrosis—Betamethasone—hematologic cancer	0.000609	0.000876	CcSEcCtD
Naphazoline—Dizziness—Irinotecan—hematologic cancer	0.000609	0.000875	CcSEcCtD
Naphazoline—Eye disorder—Methotrexate—hematologic cancer	0.000603	0.000868	CcSEcCtD
Naphazoline—Asthenia—Cisplatin—hematologic cancer	0.0006	0.000862	CcSEcCtD
Naphazoline—Sweating—Doxorubicin—hematologic cancer	0.000597	0.000859	CcSEcCtD
Naphazoline—Headache—Vincristine—hematologic cancer	0.000592	0.000852	CcSEcCtD
Naphazoline—Nausea—Carmustine—hematologic cancer	0.000588	0.000846	CcSEcCtD
Naphazoline—Nausea—Alitretinoin—hematologic cancer	0.000583	0.000838	CcSEcCtD
Naphazoline—Hypertension—Prednisone—hematologic cancer	0.000581	0.000835	CcSEcCtD
Naphazoline—Headache—Mitoxantrone—hematologic cancer	0.000577	0.000829	CcSEcCtD
Naphazoline—Headache—Irinotecan—hematologic cancer	0.000577	0.000829	CcSEcCtD
Naphazoline—Nausea—Ifosfamide—hematologic cancer	0.000576	0.000828	CcSEcCtD
Naphazoline—Discomfort—Prednisone—hematologic cancer	0.000566	0.000813	CcSEcCtD
Naphazoline—Eye disorder—Epirubicin—hematologic cancer	0.000565	0.000812	CcSEcCtD
Naphazoline—Erythema—Methotrexate—hematologic cancer	0.000562	0.000808	CcSEcCtD
Naphazoline—Headache—Gemcitabine—hematologic cancer	0.000562	0.000808	CcSEcCtD
Naphazoline—Nausea—Vincristine—hematologic cancer	0.000562	0.000807	CcSEcCtD
Naphazoline—Asthenia—Etoposide—hematologic cancer	0.000549	0.00079	CcSEcCtD
Naphazoline—Nausea—Irinotecan—hematologic cancer	0.000547	0.000786	CcSEcCtD
Naphazoline—Nausea—Mitoxantrone—hematologic cancer	0.000547	0.000786	CcSEcCtD
Naphazoline—Nausea—Gemcitabine—hematologic cancer	0.000533	0.000766	CcSEcCtD
Naphazoline—Hyperhidrosis—Prednisone—hematologic cancer	0.000531	0.000763	CcSEcCtD
Naphazoline—Vision blurred—Methotrexate—hematologic cancer	0.00053	0.000762	CcSEcCtD
Naphazoline—Erythema—Epirubicin—hematologic cancer	0.000526	0.000756	CcSEcCtD
Naphazoline—Eye disorder—Doxorubicin—hematologic cancer	0.000522	0.000751	CcSEcCtD
Naphazoline—Tension—Epirubicin—hematologic cancer	0.000516	0.000742	CcSEcCtD
Naphazoline—Nervousness—Epirubicin—hematologic cancer	0.000511	0.000735	CcSEcCtD
Naphazoline—Dizziness—Etoposide—hematologic cancer	0.000506	0.000728	CcSEcCtD
Naphazoline—Dizziness—Prednisolone—hematologic cancer	0.000499	0.000718	CcSEcCtD
Naphazoline—Asthenia—Triamcinolone—hematologic cancer	0.000498	0.000717	CcSEcCtD
Naphazoline—Nausea—Cisplatin—hematologic cancer	0.000497	0.000714	CcSEcCtD
Naphazoline—Vision blurred—Epirubicin—hematologic cancer	0.000496	0.000713	CcSEcCtD
Naphazoline—Erythema—Doxorubicin—hematologic cancer	0.000487	0.0007	CcSEcCtD
Naphazoline—Headache—Etoposide—hematologic cancer	0.00048	0.00069	CcSEcCtD
Naphazoline—Tension—Doxorubicin—hematologic cancer	0.000478	0.000687	CcSEcCtD
Naphazoline—Headache—Prednisolone—hematologic cancer	0.000473	0.00068	CcSEcCtD
Naphazoline—Discomfort—Methotrexate—hematologic cancer	0.000473	0.00068	CcSEcCtD
Naphazoline—Nervousness—Doxorubicin—hematologic cancer	0.000473	0.00068	CcSEcCtD
Naphazoline—Dizziness—Triamcinolone—hematologic cancer	0.000459	0.000661	CcSEcCtD
Naphazoline—Vision blurred—Doxorubicin—hematologic cancer	0.000459	0.00066	CcSEcCtD
Naphazoline—Nausea—Etoposide—hematologic cancer	0.000455	0.000654	CcSEcCtD
Naphazoline—Hypertension—Epirubicin—hematologic cancer	0.000454	0.000653	CcSEcCtD
Naphazoline—Asthenia—Dexamethasone—hematologic cancer	0.000452	0.00065	CcSEcCtD
Naphazoline—Asthenia—Betamethasone—hematologic cancer	0.000452	0.00065	CcSEcCtD
Naphazoline—Nausea—Prednisolone—hematologic cancer	0.000449	0.000645	CcSEcCtD
Naphazoline—Hyperhidrosis—Methotrexate—hematologic cancer	0.000443	0.000638	CcSEcCtD
Naphazoline—Discomfort—Epirubicin—hematologic cancer	0.000442	0.000636	CcSEcCtD
Naphazoline—Headache—Triamcinolone—hematologic cancer	0.000435	0.000626	CcSEcCtD
Naphazoline—Hypertension—Doxorubicin—hematologic cancer	0.00042	0.000604	CcSEcCtD
Naphazoline—Dizziness—Betamethasone—hematologic cancer	0.000417	0.000599	CcSEcCtD
Naphazoline—Dizziness—Dexamethasone—hematologic cancer	0.000417	0.000599	CcSEcCtD
Naphazoline—Hyperhidrosis—Epirubicin—hematologic cancer	0.000415	0.000597	CcSEcCtD
Naphazoline—Nausea—Triamcinolone—hematologic cancer	0.000413	0.000593	CcSEcCtD
Naphazoline—Discomfort—Doxorubicin—hematologic cancer	0.000409	0.000589	CcSEcCtD
Naphazoline—Somnolence—Methotrexate—hematologic cancer	0.000408	0.000586	CcSEcCtD
Naphazoline—Headache—Dexamethasone—hematologic cancer	0.000395	0.000568	CcSEcCtD
Naphazoline—Headache—Betamethasone—hematologic cancer	0.000395	0.000568	CcSEcCtD
Naphazoline—Asthenia—Prednisone—hematologic cancer	0.000394	0.000566	CcSEcCtD
Naphazoline—Hyperhidrosis—Doxorubicin—hematologic cancer	0.000384	0.000552	CcSEcCtD
Naphazoline—Somnolence—Epirubicin—hematologic cancer	0.000382	0.000549	CcSEcCtD
Naphazoline—Nausea—Dexamethasone—hematologic cancer	0.000374	0.000538	CcSEcCtD
Naphazoline—Nausea—Betamethasone—hematologic cancer	0.000374	0.000538	CcSEcCtD
Naphazoline—Dizziness—Prednisone—hematologic cancer	0.000363	0.000522	CcSEcCtD
Naphazoline—Somnolence—Doxorubicin—hematologic cancer	0.000353	0.000508	CcSEcCtD
Naphazoline—Headache—Prednisone—hematologic cancer	0.000344	0.000494	CcSEcCtD
Naphazoline—Asthenia—Methotrexate—hematologic cancer	0.000329	0.000473	CcSEcCtD
Naphazoline—Nausea—Prednisone—hematologic cancer	0.000326	0.000469	CcSEcCtD
Naphazoline—Asthenia—Epirubicin—hematologic cancer	0.000308	0.000443	CcSEcCtD
Naphazoline—Dizziness—Methotrexate—hematologic cancer	0.000303	0.000436	CcSEcCtD
Naphazoline—Headache—Methotrexate—hematologic cancer	0.000287	0.000413	CcSEcCtD
Naphazoline—Asthenia—Doxorubicin—hematologic cancer	0.000285	0.00041	CcSEcCtD
Naphazoline—Dizziness—Epirubicin—hematologic cancer	0.000284	0.000408	CcSEcCtD
Naphazoline—Nausea—Methotrexate—hematologic cancer	0.000272	0.000392	CcSEcCtD
Naphazoline—Headache—Epirubicin—hematologic cancer	0.000269	0.000387	CcSEcCtD
Naphazoline—Dizziness—Doxorubicin—hematologic cancer	0.000263	0.000378	CcSEcCtD
Naphazoline—Nausea—Epirubicin—hematologic cancer	0.000255	0.000367	CcSEcCtD
Naphazoline—Headache—Doxorubicin—hematologic cancer	0.000249	0.000358	CcSEcCtD
Naphazoline—Nausea—Doxorubicin—hematologic cancer	0.000236	0.000339	CcSEcCtD
Naphazoline—ADRA2A—Signaling Pathways—FGF1—hematologic cancer	3.04e-05	0.00012	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—MAPK14—hematologic cancer	3.03e-05	0.000119	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—CD80—hematologic cancer	3.02e-05	0.000119	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—PIK3CG—hematologic cancer	3.01e-05	0.000119	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—KIT—hematologic cancer	3.01e-05	0.000119	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling by GPCR—NRAS—hematologic cancer	3.01e-05	0.000119	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—FOXO1—hematologic cancer	3e-05	0.000118	CbGpPWpGaD
Naphazoline—ADRA2A—GPCR downstream signaling—IL2—hematologic cancer	3e-05	0.000118	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—PDGFRB—hematologic cancer	2.99e-05	0.000118	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—ESR1—hematologic cancer	2.97e-05	0.000117	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—PIK3CB—hematologic cancer	2.96e-05	0.000117	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—PTPN11—hematologic cancer	2.96e-05	0.000116	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—PIK3CD—hematologic cancer	2.96e-05	0.000116	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—IL2RA—hematologic cancer	2.95e-05	0.000116	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—PDGFRA—hematologic cancer	2.95e-05	0.000116	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—FN1—hematologic cancer	2.94e-05	0.000116	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—JAK1—hematologic cancer	2.94e-05	0.000116	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—PRKCG—hematologic cancer	2.94e-05	0.000116	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling by GPCR—IL2—hematologic cancer	2.93e-05	0.000115	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—ALB—hematologic cancer	2.92e-05	0.000115	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—TERT—hematologic cancer	2.92e-05	0.000115	CbGpPWpGaD
Naphazoline—ADRA2A—Hemostasis—HRAS—hematologic cancer	2.91e-05	0.000115	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—BAD—hematologic cancer	2.9e-05	0.000114	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—NFKBIA—hematologic cancer	2.9e-05	0.000114	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling by GPCR—MAPK3—hematologic cancer	2.88e-05	0.000114	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—NOTCH1—hematologic cancer	2.88e-05	0.000113	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—CREB1—hematologic cancer	2.87e-05	0.000113	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—PDGFB—hematologic cancer	2.85e-05	0.000112	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—BRAF—hematologic cancer	2.83e-05	0.000111	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—CD80—hematologic cancer	2.82e-05	0.000111	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—KIT—hematologic cancer	2.81e-05	0.000111	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—PIK3CG—hematologic cancer	2.81e-05	0.000111	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling by GPCR—NRAS—hematologic cancer	2.81e-05	0.000111	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—CCL2—hematologic cancer	2.8e-05	0.00011	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—IL6R—hematologic cancer	2.79e-05	0.00011	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—PIK3R1—hematologic cancer	2.79e-05	0.00011	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—CREBBP—hematologic cancer	2.79e-05	0.00011	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—TSC2—hematologic cancer	2.78e-05	0.00011	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—PTPN11—hematologic cancer	2.76e-05	0.000109	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—IL2RA—hematologic cancer	2.74e-05	0.000108	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—PIK3CG—hematologic cancer	2.73e-05	0.000108	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—IL2—hematologic cancer	2.72e-05	0.000107	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—TERT—hematologic cancer	2.71e-05	0.000107	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling by GPCR—MAPK3—hematologic cancer	2.69e-05	0.000106	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—FGFR3—hematologic cancer	2.68e-05	0.000105	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—CREB1—hematologic cancer	2.68e-05	0.000105	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—MAP2K1—hematologic cancer	2.66e-05	0.000105	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—MAPK14—hematologic cancer	2.65e-05	0.000104	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—PIK3CD—hematologic cancer	2.65e-05	0.000104	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—PDGFB—hematologic cancer	2.65e-05	0.000104	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—BRAF—hematologic cancer	2.64e-05	0.000104	CbGpPWpGaD
Naphazoline—ADRA2B—GPCR downstream signaling—PIK3CA—hematologic cancer	2.62e-05	0.000103	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—CCL2—hematologic cancer	2.62e-05	0.000103	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—IL6R—hematologic cancer	2.61e-05	0.000103	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—CREBBP—hematologic cancer	2.61e-05	0.000103	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—ESR1—hematologic cancer	2.6e-05	0.000102	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling by GPCR—KRAS—hematologic cancer	2.59e-05	0.000102	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—TSC2—hematologic cancer	2.59e-05	0.000102	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—PIK3CB—hematologic cancer	2.58e-05	0.000101	CbGpPWpGaD
Naphazoline—ADRA2A—Hemostasis—AKT1—hematologic cancer	2.57e-05	0.000101	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—FN1—hematologic cancer	2.57e-05	0.000101	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—NFKBIA—hematologic cancer	2.54e-05	0.0001	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—BAD—hematologic cancer	2.54e-05	0.0001	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—FGF2—hematologic cancer	2.53e-05	9.98e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—CREBBP—hematologic cancer	2.53e-05	9.98e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—NOTCH1—hematologic cancer	2.51e-05	9.9e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—PIK3R1—hematologic cancer	2.5e-05	9.84e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—MAP2K1—hematologic cancer	2.49e-05	9.8e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—FGFR3—hematologic cancer	2.49e-05	9.8e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—PIK3CD—hematologic cancer	2.47e-05	9.74e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—MAPK14—hematologic cancer	2.46e-05	9.7e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—CD80—hematologic cancer	2.46e-05	9.7e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—KIT—hematologic cancer	2.46e-05	9.68e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—PIK3CG—hematologic cancer	2.46e-05	9.68e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling by GPCR—NRAS—hematologic cancer	2.46e-05	9.68e-05	CbGpPWpGaD
Naphazoline—ADRA2C—GPCR downstream signaling—PIK3CA—hematologic cancer	2.45e-05	9.64e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—JAK2—hematologic cancer	2.43e-05	9.57e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling by GPCR—KRAS—hematologic cancer	2.42e-05	9.53e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—ESR1—hematologic cancer	2.42e-05	9.52e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—PTPN11—hematologic cancer	2.41e-05	9.51e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—PIK3CD—hematologic cancer	2.4e-05	9.46e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—FN1—hematologic cancer	2.39e-05	9.4e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling by GPCR—PIK3CA—hematologic cancer	2.38e-05	9.38e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—MDM2—hematologic cancer	2.37e-05	9.34e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—ALB—hematologic cancer	2.37e-05	9.34e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—FGF2—hematologic cancer	2.37e-05	9.32e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—BAD—hematologic cancer	2.36e-05	9.29e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—NFKBIA—hematologic cancer	2.36e-05	9.29e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling by GPCR—MAPK3—hematologic cancer	2.35e-05	9.27e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—CREB1—hematologic cancer	2.34e-05	9.22e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—NOTCH1—hematologic cancer	2.34e-05	9.2e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—PIK3R1—hematologic cancer	2.33e-05	9.19e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—BRAF—hematologic cancer	2.31e-05	9.1e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—MTOR—hematologic cancer	2.31e-05	9.09e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—PIK3CB—hematologic cancer	2.31e-05	9.09e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—CCL2—hematologic cancer	2.29e-05	9.02e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—CD80—hematologic cancer	2.29e-05	9.01e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—KIT—hematologic cancer	2.28e-05	9e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—PIK3CG—hematologic cancer	2.28e-05	9e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—NRAS—hematologic cancer	2.28e-05	9e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—IL6R—hematologic cancer	2.28e-05	8.99e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—CREBBP—hematologic cancer	2.28e-05	8.98e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—JAK2—hematologic cancer	2.27e-05	8.94e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—PIK3R1—hematologic cancer	2.27e-05	8.93e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—PTPN11—hematologic cancer	2.24e-05	8.84e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—PTEN—hematologic cancer	2.23e-05	8.77e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling by GPCR—PIK3CA—hematologic cancer	2.22e-05	8.76e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—MDM2—hematologic cancer	2.21e-05	8.72e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling by GPCR—HRAS—hematologic cancer	2.2e-05	8.67e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—MAPK3—hematologic cancer	2.19e-05	8.62e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—MAP2K1—hematologic cancer	2.18e-05	8.57e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—CREB1—hematologic cancer	2.17e-05	8.56e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—CDKN1B—hematologic cancer	2.16e-05	8.53e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—PIK3CD—hematologic cancer	2.16e-05	8.51e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—PIK3CB—hematologic cancer	2.15e-05	8.49e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—MTOR—hematologic cancer	2.15e-05	8.49e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—BRAF—hematologic cancer	2.15e-05	8.46e-05	CbGpPWpGaD
Naphazoline—ADRA2B—GPCR downstream signaling—AKT1—hematologic cancer	2.14e-05	8.43e-05	CbGpPWpGaD
Naphazoline—ADRA1A—GPCR downstream signaling—PIK3CA—hematologic cancer	2.14e-05	8.43e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—CCL2—hematologic cancer	2.13e-05	8.38e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—EP300—hematologic cancer	2.12e-05	8.36e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—CASP3—hematologic cancer	2.12e-05	8.36e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—IL6R—hematologic cancer	2.12e-05	8.35e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—IL2—hematologic cancer	2.12e-05	8.34e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—CREBBP—hematologic cancer	2.12e-05	8.34e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling by GPCR—KRAS—hematologic cancer	2.12e-05	8.33e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling by GPCR—IL6—hematologic cancer	2.11e-05	8.3e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—PIK3CB—hematologic cancer	2.09e-05	8.24e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—FGF2—hematologic cancer	2.07e-05	8.15e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—CCND1—hematologic cancer	2.06e-05	8.13e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—JUN—hematologic cancer	2.06e-05	8.12e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling by GPCR—HRAS—hematologic cancer	2.06e-05	8.1e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—PIK3R1—hematologic cancer	2.04e-05	8.04e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—CDKN1B—hematologic cancer	2.02e-05	7.96e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—MAP2K1—hematologic cancer	2.02e-05	7.96e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—PIK3CD—hematologic cancer	2.01e-05	7.91e-05	CbGpPWpGaD
Naphazoline—ADRA2C—GPCR downstream signaling—AKT1—hematologic cancer	2e-05	7.88e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—CDKN1A—hematologic cancer	2e-05	7.87e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—PTEN—hematologic cancer	1.99e-05	7.85e-05	CbGpPWpGaD
Naphazoline—ADRA2A—GPCR downstream signaling—PIK3CA—hematologic cancer	1.99e-05	7.83e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—JAK2—hematologic cancer	1.98e-05	7.81e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—CASP3—hematologic cancer	1.98e-05	7.81e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—IL2—hematologic cancer	1.98e-05	7.79e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling by GPCR—IL6—hematologic cancer	1.97e-05	7.76e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—KRAS—hematologic cancer	1.97e-05	7.74e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—MAPK8—hematologic cancer	1.95e-05	7.68e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling by GPCR—AKT1—hematologic cancer	1.94e-05	7.66e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling by GPCR—PIK3CA—hematologic cancer	1.94e-05	7.66e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—MDM2—hematologic cancer	1.94e-05	7.63e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—CCND1—hematologic cancer	1.93e-05	7.6e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—JUN—hematologic cancer	1.92e-05	7.58e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—FGF2—hematologic cancer	1.92e-05	7.57e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—EP300—hematologic cancer	1.9e-05	7.49e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—PIK3R1—hematologic cancer	1.9e-05	7.47e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—MTOR—hematologic cancer	1.88e-05	7.42e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—PIK3CB—hematologic cancer	1.88e-05	7.42e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—CDKN1A—hematologic cancer	1.87e-05	7.35e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—PTEN—hematologic cancer	1.86e-05	7.33e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—SRC—hematologic cancer	1.85e-05	7.28e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—JAK2—hematologic cancer	1.84e-05	7.26e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—MAPK8—hematologic cancer	1.82e-05	7.17e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling by GPCR—AKT1—hematologic cancer	1.82e-05	7.15e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—PTEN—hematologic cancer	1.81e-05	7.12e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—PIK3CA—hematologic cancer	1.81e-05	7.11e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—VEGFA—hematologic cancer	1.8e-05	7.09e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—MDM2—hematologic cancer	1.8e-05	7.09e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling by GPCR—HRAS—hematologic cancer	1.8e-05	7.08e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—STAT3—hematologic cancer	1.78e-05	7.02e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—NRAS—hematologic cancer	1.78e-05	7e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—EP300—hematologic cancer	1.78e-05	6.99e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—CDKN1B—hematologic cancer	1.77e-05	6.96e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—PIK3CB—hematologic cancer	1.75e-05	6.89e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—MTOR—hematologic cancer	1.75e-05	6.89e-05	CbGpPWpGaD
Naphazoline—ADRA1A—GPCR downstream signaling—AKT1—hematologic cancer	1.75e-05	6.89e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—CASP3—hematologic cancer	1.73e-05	6.82e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—IL2—hematologic cancer	1.73e-05	6.81e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—SRC—hematologic cancer	1.73e-05	6.8e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—EP300—hematologic cancer	1.72e-05	6.79e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling by GPCR—IL6—hematologic cancer	1.72e-05	6.78e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—MAPK3—hematologic cancer	1.7e-05	6.71e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—CCND1—hematologic cancer	1.69e-05	6.64e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—JUN—hematologic cancer	1.68e-05	6.63e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—VEGFA—hematologic cancer	1.68e-05	6.62e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—HRAS—hematologic cancer	1.67e-05	6.58e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—STAT3—hematologic cancer	1.66e-05	6.56e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—NRAS—hematologic cancer	1.66e-05	6.54e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—MYC—hematologic cancer	1.66e-05	6.52e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—TGFB1—hematologic cancer	1.65e-05	6.51e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—CDKN1B—hematologic cancer	1.64e-05	6.47e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—CDKN1A—hematologic cancer	1.63e-05	6.43e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—PTEN—hematologic cancer	1.63e-05	6.41e-05	CbGpPWpGaD
Naphazoline—ADRA2A—GPCR downstream signaling—AKT1—hematologic cancer	1.62e-05	6.4e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—CASP3—hematologic cancer	1.61e-05	6.34e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—IL2—hematologic cancer	1.61e-05	6.33e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—IL6—hematologic cancer	1.6e-05	6.3e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—MAPK8—hematologic cancer	1.59e-05	6.27e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—MAPK3—hematologic cancer	1.59e-05	6.27e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling by GPCR—AKT1—hematologic cancer	1.59e-05	6.25e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—PIK3CA—hematologic cancer	1.57e-05	6.19e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—CCND1—hematologic cancer	1.57e-05	6.17e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—JUN—hematologic cancer	1.56e-05	6.16e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—EP300—hematologic cancer	1.55e-05	6.11e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—MYC—hematologic cancer	1.55e-05	6.09e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—TGFB1—hematologic cancer	1.54e-05	6.08e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—KRAS—hematologic cancer	1.53e-05	6.03e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—CDKN1A—hematologic cancer	1.52e-05	5.97e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—PTEN—hematologic cancer	1.51e-05	5.96e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—SRC—hematologic cancer	1.51e-05	5.95e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—MAPK8—hematologic cancer	1.48e-05	5.83e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—AKT1—hematologic cancer	1.48e-05	5.81e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—VEGFA—hematologic cancer	1.47e-05	5.79e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—STAT3—hematologic cancer	1.46e-05	5.73e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—NRAS—hematologic cancer	1.45e-05	5.72e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—EP300—hematologic cancer	1.44e-05	5.68e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—KRAS—hematologic cancer	1.43e-05	5.63e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—PIK3CA—hematologic cancer	1.41e-05	5.54e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—SRC—hematologic cancer	1.4e-05	5.52e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—MAPK3—hematologic cancer	1.39e-05	5.48e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—VEGFA—hematologic cancer	1.37e-05	5.38e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—TP53—hematologic cancer	1.36e-05	5.36e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—MYC—hematologic cancer	1.35e-05	5.33e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—STAT3—hematologic cancer	1.35e-05	5.33e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—TGFB1—hematologic cancer	1.35e-05	5.31e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—NRAS—hematologic cancer	1.35e-05	5.31e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—PIK3CA—hematologic cancer	1.31e-05	5.17e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—HRAS—hematologic cancer	1.3e-05	5.12e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—MAPK3—hematologic cancer	1.29e-05	5.09e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—AKT1—hematologic cancer	1.28e-05	5.05e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—PIK3CA—hematologic cancer	1.28e-05	5.03e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—TP53—hematologic cancer	1.27e-05	5e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—MYC—hematologic cancer	1.26e-05	4.95e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—TGFB1—hematologic cancer	1.25e-05	4.94e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—KRAS—hematologic cancer	1.25e-05	4.92e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—IL6—hematologic cancer	1.24e-05	4.9e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—HRAS—hematologic cancer	1.22e-05	4.79e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—IL6—hematologic cancer	1.16e-05	4.58e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—KRAS—hematologic cancer	1.16e-05	4.57e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—AKT1—hematologic cancer	1.15e-05	4.52e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—PIK3CA—hematologic cancer	1.15e-05	4.52e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—TP53—hematologic cancer	1.11e-05	4.38e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—AKT1—hematologic cancer	1.07e-05	4.23e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—PIK3CA—hematologic cancer	1.07e-05	4.2e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—HRAS—hematologic cancer	1.06e-05	4.18e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—AKT1—hematologic cancer	1.04e-05	4.11e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—TP53—hematologic cancer	1.03e-05	4.07e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—IL6—hematologic cancer	1.02e-05	4e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—HRAS—hematologic cancer	9.87e-06	3.89e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—IL6—hematologic cancer	9.45e-06	3.72e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—AKT1—hematologic cancer	9.38e-06	3.69e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—AKT1—hematologic cancer	8.71e-06	3.43e-05	CbGpPWpGaD
